John P Gibbs

List of Publications by Citations

26 papers	1,572 citations	16 h-index	26 g-index
26 ext. papers	1,682 ext. citations	4.2 avg, IF	3.81 L-index

#	Paper	IF	Citations
26	The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. *Drug Metabolism and Disposition*, **2005**, 33, 165-74	4	408
25	Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. *Journal of the American College of Cardiology*, **2012**, 60, 1888-98	15.1	197
24	Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 313, 1254-62	4.7	155
23	Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. *Drug Metabolism and Disposition*, **2006**, 34, 1443-7	4	143
22	Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. *Clinical Pharmacokinetics*, **2011**, 50, 131-42	6.2	118
21	Plasma concentration monitoring of busulfan: does it improve clinical outcome?. *Clinical Pharmacokinetics*, **2000**, 39, 155-65	6.2	118
20	The Impact of Obesity and Disease on Busulfan Oral Clearance in Adults. *Blood*, **1999**, 93, 4436-4440	2.2	86
19	Reaction phenotyping in drug discovery: moving forward with confidence?. *Current Drug Metabolism*, **2003**, 4, 527-34	3.5	55
18	Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. *Clinical Pharmacokinetics*, **2018**, 57, 769-779	6.2	40
17	Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism. *Drug Metabolism and Disposition*, **2006**, 34, 1516-22	4	37
16	Prediction of exposure-response relationships to support first-in-human study design. *AAPS Journal* , **2010**, 12, 750-8	3.7	34
15	Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. *Journal of Clinical Pharmacology*, **2012**, 52, 1494-505	2.9	29
14	A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design. *MAbs*, **2014**, 6, 1094-102	6.6	26
13	Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). *Journal of Clinical Pharmacology*, **2017**, 57, 616-626	2.9	23
12	Application of in vivo animal models to characterize the pharmacokinetic and pharmacodynamic properties of drug candidates in discovery settings. *Combinatorial Chemistry and High Throughput Screening*, **2010**, 13, 207-18	1.3	19
11	Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment. *Journal of Clinical Pharmacology*, **2017**, 57, 513-523	2.9	16
10	Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum. *MAbs*, **2014**, 6, 1103-13	6.6	16

9	Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. *JAMA Cardiology*, **2017**, 2, 556-560	16.2	15
8	Bedside to Bench: Integrating Quantitative Clinical Pharmacology and Reverse Translation to Optimize Drug Development. *Clinical Pharmacology and Therapeutics*, **2018**, 103, 196-198	6.1	8
7	Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. *Clinical Pharmacokinetics*, **2018**, 57, 71-85	6.2	7
6	Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2018**, 23, 423-432	2.6	7
5	Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse. *Journal of Clinical Pharmacology*, **2019**, 59, 625-637	2.9	6
4	Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety. *Clinical Pharmacology in Drug Development*, **2019**, 8, 281-289	2.3	3
3	SRM-based measurements of proprotein convertase subtilisin/kexin type 9 and lipoprotein(a) kinetics in nonhuman primate serum. *Bioanalysis*, **2016**, 8, 2551-2563	2.1	3
2	Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia. *Journal of Pharmacokinetics and Pharmacodynamics*, **2018**, 45, 505-522	2.7	3
1	Pharmacometrics of Hyperlipidemia. *AAPS Advances in the Pharmaceutical Sciences Series*, **2014**, 539-562	0.5	